Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

David Seitz

Physician Assistant, Medical Loveland, CO Physician Assistant

NPI 1235169194 CMS profile 11191341

1708 Boise Ave, Loveland, CO 80538

Open in the dashboard

General payments

$11,375

543 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Seitz of Loveland, CO is reported in the CMS Open Payments database as having received $11,375 across 543 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,574 113
2024 General $2,770 135
2023 General $2,564 127
2022 General $1,840 87
2021 General $1,627 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Seitz
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to David Seitz were reported at $2,574. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year David Seitz Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,627 $156 $41–$563 $132
2022 $1,840 $185 $55–$649 $149
2023 $2,564 $199 $58–$717 $160
2024 $2,770 $206 $62–$740 $164
2025 $2,574 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,538 70 payments
  2. AbbVie, Inc. $1,522 80 payments
  3. Novartis Pharmaceuticals Corporation $969 69 payments
  4. Regeneron Healthcare Solutions, Inc. $962 29 payments
  5. Genzyme Corporation $825 30 payments
  6. Sun Pharmaceutical Industries Inc. $742 27 payments
  7. Amgen Inc. $622 33 payments
  8. E.R. Squibb & Sons, L.L.C. $597 28 payments
  9. Lilly USA, LLC $505 31 payments
  10. UCB, Inc. $501 18 payments
  11. Other $2,591 128 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,417 533 payments
  2. Education $958 10 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,360 53 payments
  2. DUPIXENT Immunology $1,067 43 payments
  3. SKYRIZI $720 40 payments
  4. Otezla $609 32 payments
  5. SOTYKTU $572 27 payments
  6. DUPIXENT Inflammation And Immunology $507 17 payments
  7. COSENTYX $499 37 payments
  8. RINVOQ $487 23 payments
  9. ADBRY $430 19 payments
  10. TALTZ $428 27 payments
  11. Other $6,078 338 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

737

Median for Physician Assistant: 241

Drug cost

$21,274

Median for Physician Assistant: $4,110

Branded share of claims

5.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 154 $5,057
Fluorouracil Generic 72 $4,737
Doxycycline Monohydrate Generic 117 $3,225
Ciclopirox Generic 41 $2,313
Triamcinolone Acetonide Generic 103 $1,599
Dapsone Generic 13 $858
Ciclopirox Ciclopirox Olamine Brand 26 $724
Doxycycline Hyclate Generic 25 $662
Ketoconazole Generic 40 $553
Metronidazole Generic 11 $489

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$114,757

Medicare's payments for the services billed

Medicare patients

602

Average age 76

Services billed

3,730

208 women, 394 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 41%
Ischemic heart disease 25%
Chronic kidney disease 19%
Depression 19%
Cancer 17%
Atrial fibrillation 15%
Diabetes 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $313
  • GENZYME CORPORATION $159
$473 — —
TREMFYA
  • Janssen Biotech, Inc. $400
$400 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $262
$262 — —
SKYRIZI
  • AbbVie, Inc. $204
$204 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $193
$193 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

543 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record